Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.87 USD
Change Today -0.0098 / -1.12%
Volume 1.5M
CYTX On Other Exchanges
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

cytori therapeutics inc (CYTX) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/12/14 - $2.55
52 Week Low
11/12/14 - $0.36
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

cytori therapeutics inc (CYTX) Related Bloomberg News

View More Bloomberg News

cytori therapeutics inc (CYTX) Related Businessweek News

View More BusinessWeek News

cytori therapeutics inc (CYTX) Details

Cytori Therapeutics, Inc., a biotechnology company, develops cell therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy consisting of a heterogeneous population of specialized cells, including stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence, and thermal burns combined with radiation injury. It also offers Celution System devices and consumable sets, and other ancillary products for the customers developing new therapeutic applications for Cytori Cell Therapy in Europe, Japan, and other regions. The company markets its products to hospitals, clinics, tissue banks, and stem cell banking companies through direct sales representatives, distributors, and partners worldwide. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.

78 Employees
Last Reported Date: 03/16/15
Founded in 1996

cytori therapeutics inc (CYTX) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $437.4K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $79.1K
President of Asia Pacific
Total Annual Compensation: $367.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2014.

cytori therapeutics inc (CYTX) Key Developments

Cytori Therapeutics Provides Twelve Month Data Update on Scleradec-I Trial

Cytori Therapeutics, Inc. announced preliminary 12 month follow-up data from the 12 patient investigator initiated Scleradec-I clinical trial conducted by Prof. B. Granel and Prof. G. Magalon from the Assistance Publique des H pitaux de Marseille. In the previously published six month follow-up data, Cytori's ECCS-50 therapeutic showed: Improvement in Cochin Hand Function Scale (CHFS) from mean of 48.5 at baseline to 21.2 at six months; Improvement in Hand Pain (Visual Analog Scale) from mean of 59.4 at baseline to 17.8 at six months; Improvement in Raynaud's Condition Score (RCS) from mean of 7.2 at baseline to 2.9 at six months; Improvement in Scleroderma Health Assessment Questionnaire (SHAQ) score from mean of 1.4 at baseline to 0.8 at six months. A preliminary assessment for 12 month follow-up data has been reviewed by the company which management believes reflects: No reports of adverse events or safety concerns; Average values for CHFS, RCS, and SHAQ score are statistically consistent with those at the 6 month follow up visit; While the average hand pain at 12 months was lower than that at baseline (reflecting overall symptom improvement over baseline), there was an approximately 50% reduction in the average therapeutic benefit on hand pain from six to twelve months The investigators have prepared and submitted for publication a scientific manuscript based on final 12 month data.

The European Commission Designates Cytori’s ECCS-50 Cellular Therapeutic as an Orphan Medicinal Product for the Treatment of Scleroderma

Cytori Therapeutics, Inc. announced that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products, has designated Cytori’s ECCS-50 cellular therapeutic as an orphan medicinal product for the treatment of scleroderma. This designation marks the first autologous adipose derived cell therapy for scleroderma granted orphan status in the European Union (EU). Cytori is currently working with scleroderma centers in France led by the Assistance Publique des Hôpitaux de Marseille to begin a 40 patient EU pivotal trial called SCLERADEC-II. The trial is a follow-up controlled trial to the first SCLERADEC trial published last August (Granel et al. Annals of the Rheumatic Diseases, 2014). If successful, this trial would potentially lead to EMA approval of Cytori’s lead therapeutic for this indication in the EU, as an ATMP or Advanced Therapy Medicinal Product.

Cytori Therapeutics Receives China Opening Product Purchase Order from Licensee

Cytori Therapeutics, Inc. announced that its exclusive licensee, Lorem Vascular, has been granted regulatory clearance for the Cytori Celution System by the State Food and Drug Administration of the People's Republic of China (CFDA). This regulatory clearance officially makes Cytori's Celution System available in the large healthcare market in the world and triggers a substantial 2015 product purchase order for Cytori from Lorem Vascular. Cytori's exclusive licensee in the region, Lorem Vascular, has worked closely with Cytori during the last year preparing for CFDA clearance and planning for commercial introduction of the Celution family of products in China.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTX:US $0.87 USD -0.0098

CYTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.16 USD -0.04
Cardica Inc $0.42 USD +0.0065
NeoStem Inc $2.79 USD -0.09
Nuo Therapeutics Inc $0.22 USD 0.00
StemCells Inc $0.61 USD +0.0044
View Industry Companies

Industry Analysis


Industry Average

Valuation CYTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTORI THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at